bisphosphonates

Osteoporosis

Epidemiology

 

1/3 caucasian women > 64

 

Risk Factors

 

Insufficient bone mass at time of skeletal maturity

- peak bone mass is achieved at age 25

 

Rapid loss of bone after menopause

 

Low body weight / weight loss / history of smoking / steroids

 

Primary

 

Type 1

- postmenopausal

- high turnover / osteoclast mediated

- F x 6

Management

Mirels Prediction system for Pathological Fracture

 

Clin Orthop 1989 

- 38 patients treated with DXRT without surgery 

- most breast cancer

- developed scoring system

- predicts post DXRT fracture risk in preDXRT long bones

- risk of fracture within 6 months 

- irradiated without fixation

 

Four risk factors

 

Atypical Femur Fractures

Atypical Femur FracturesAtypical femur fracture xray

 

Site

 

Subtrochanteric

Lateral femoral shaft

 

Aetiology

 

Stress fractures

 

Associated with long term bisphonate use

 

Bisphosphonates

 

Black et al. NEJM 2020

- reduction of hip fracture risk v risk of atypical femur fracture

- 10 year period

Management

Management Summary

 

Stage 0

 

Natural history mixed

- depends on size of lesion and diagnosis

- treat if becomes asymptomatic

- may benefit from bisphosphonates

 

Stage 1 / Normal X-ray, abnormal MRI

 

Forage: 80% G/E

Bisphosphonates

 

Stage 2 / Abnormal X-ray with cysts and sclerosis

 

A:  As for Stage I

Avascular necrosis

Shoulder AVN

 

Epidemiology

 

Much less common than hip OA

- usually presents late

 

Aetiology

 

Similar causes as hip (AS IT GRIPS 3C)

 

Alcohol / Steroid / Trauma / Idiopathic

 

Gauchers

 

RA / RTx

 

Sickle Cell 

Osteogenesis Imperfecta

Defect

 

Abnormality of type 1 collagen

- amino acid substitution of glycine with another amino acid

- prevents triple helix formation

 

Many many deformities described

- some 286 mutations of Type 1 collagen described

 

Sillence Classification

 

There are actually now 7 

 

Type I

- mild

- AD

- blue sclera